Losartan titration versus diuretic combination in type 2 diabetic patients

被引:9
|
作者
de Pablos-Velasco, PL
Toral, FP
Esmatjes, JE
Fernandez-Vega, F
de la Torre, ML
Pozuelo, A
Ruilope, LM
机构
[1] Hosp 12 Octubre, Unidad Hipertens, E-28041 Madrid, Spain
[2] H Gen Gran Canaria Dr Negrin, Las Palmas Gran Canaria, Spain
[3] H Marques Valdecilla, Santander, Spain
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] Hosp Cent Asturias, Oviedo, Spain
[6] Hosp Virgen Nieves, Granada, Spain
关键词
type; 2; diabetes; arterial hypertension; losartan; microalbuminuria; angiotensin receptor antagonists;
D O I
10.1097/00004872-200204000-00030
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Methods We compared the effects of Losartan dose titration to 100 mg versus the addition of 12.5 mg of hydrochlorothiazide, in 90 type 2 diabetic patients with microalbuminuria and blood pressure > 130/85 mmHg, receiving losartan 50 mg as initial treatment during 4 weeks. Results With the first dose of losartan, systolic (SBP) and diastolic blood pressure (DBP) decreased from 154.5 (152.1 -157.5) to 144.4 (141.3-147.5) mmHg (P < 0.001) and from 91.1 (89.4-92.8) to 84.6 (82.8-86.4) mmHg (P < 0.001), with 20 patients attaining the expected goal blood pressure (< 130/85 mmHg); albuminuria decreased from 109.8 (90.5-133.3) to 83.5 (63.6-109.5) mg per 24 h (P = 0.006). Patients not attaining the target blood pressure were randomly allocated to titration or to the combination arm. After an additional 4 weeks, patients titrated exhibited a fall in SBP and DBP from 157.1 (152.7-161.5) to 142.1 (136.4-147.8) mmHg (P < 0.001) and from 92.4 (89.5-95.3) to 83.6 (81.1-86.1) mmHg (P < 0.001); albuminuria decreased from 136.3 (97.8-189.9) to 99.7 (69.3-143.4) mg per 24 h (P = 0.002). In the combination arm, there were similar reductions in SBP and DBP from 155.3 (151.5-159.1) to 139.1 (132.1-146.1) mmHg (P < 0.001) and from 92.1 (89.3-94.9) to 80.9 (77.4-84.4) mmHg (P < 0.001); while albuminuria fell from 107.7 (82.2-141.0) to 64.2 (45.9-89.9) mg per 24 h (P = 0.001). Conclusions Losartan 50 mg was effective in reducing blood pressure and albuminuria in type 2 diabetic patients. When the blood pressure target was not reached, the two strategies tested seem to contribute similarly to further reductions in blood pressure and albuminuria. J Hypertens 20:715-719 (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:715 / 719
页数:5
相关论文
共 50 条
  • [21] Diabetic kidney disease versus non-diabetic kidney disease in type 2 diabetic patients on dialysis: An observational cohort
    Delautre, Arnaud
    Hannedouche, Thierry
    Couchoud, Cecile
    Guiserix, Jose
    Cerasuolo, Damiano
    Chantrel, Francois
    Martzloff, Jonas
    Keller, Nicolas
    Krummel, Thierry
    ENDOCRINOLOGY DIABETES & METABOLISM, 2022, 5 (04)
  • [22] Beneficial effects of rosiglitazone and losartan combination in diabetic rats
    Ateyya, Hayam
    Nader, Manar A.
    El-Sherbeeny, Nagla A.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2018, 96 (03) : 215 - 220
  • [23] Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes
    Postma, MJ
    Kruidhof, H
    de Jong-van den Berg, LTW
    de Zeeuw, D
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (09) : 1543 - 1550
  • [24] Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan-diuretic
    Kojima, Masayoshi
    Ohashi, Masuo
    Dohi, Yasuaki
    Kimura, Genjiro
    JOURNAL OF HYPERTENSION, 2013, 31 (01) : 186 - 191
  • [25] Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with α-glucosidase inhibitors
    Bando, Y
    Ushiogi, Y
    Okafuji, K
    Toya, D
    Tanaka, N
    Fujisawa, M
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1999, 27 (02) : 53 - 64
  • [26] Proteinuria in Type 2 Diabetic Patients with Renal Impairment: The Changing Face of Diabetic Nephropathy
    Packham, David K.
    Ivory, Sara E.
    Reutens, Anne T.
    Wolfe, Rory
    Rohde, Richard
    Heerspink, Hiddo Lambers
    Dwyer, Jamie P.
    Atkins, Robert C.
    Lewis, Julia
    NEPHRON CLINICAL PRACTICE, 2011, 118 (04): : C331 - C338
  • [27] CSII in type 2 diabetic patients
    Attali, Jean-Raymond
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 74 : S116 - S118
  • [28] Diabetic kidney disease: Is there a non-albuminuric phenotype in type 2 diabetic patients?
    Laranjinha, Ivo
    Matias, Patricia
    Mateus, Sofia
    Aguiar, Filipa
    Pereira, Patricia
    Santos, Miguel Perneta
    Costa, Rui
    Lourenco, Ana
    Guia, Jose
    Barata, Jose Diogo
    Campos, Luis
    NEFROLOGIA, 2016, 36 (05): : 503 - 509
  • [29] Predicting diabetic nephropathy in type 2 diabetic patients using machine learning algorithms
    Sarkhosh, Seyyed Mahdi Hosseini
    Esteghamati, Alireza
    Hemmatabadi, Mahboobeh
    Daraei, Morteza
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2022, 21 (02) : 1433 - 1441
  • [30] Losartan Affects Glomerular AKT and mTOR Phosphorylation in an Experimental Model of Type 1 Diabetic Nephropathy
    Mavroeidi, Vasiliki
    Petrakis, Ioannis
    Stylianou, Kostas
    Katsarou, Theodora
    Giannakakis, Konstantinos
    Perakis, Kostas
    Vardaki, Eleftheria
    Stratigis, Spyridon
    Ganotakis, Emmanuel
    Papavasiliou, Stathis
    Daphnis, Eugenios
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2013, 61 (06) : 433 - 443